Shares of Medivation Inc. (NASDAQ:MDVN) hit a new 52-week high during trading on Wednesday . The company traded as high as $68.37 and last traded at $66.67, with a volume of 1,139,614 shares traded. The stock had previously closed at $65.21.

MDVN has been the topic of a number of research reports. Barclays PLC boosted their price objective on shares of Medivation from $48.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, May 6th. Brean Capital reissued a “buy” rating and issued a $61.00 price objective on shares of Medivation in a research report on Saturday, May 7th. Leerink Swann reissued a “market perform” rating and issued a $64.00 price objective (up previously from $39.00) on shares of Medivation in a research report on Saturday, May 7th. BMO Capital Markets reissued a “market perform” rating and issued a $50.00 price objective (up previously from $47.00) on shares of Medivation in a research report on Monday, May 9th. Finally, Wedbush reissued an “outperform” rating and issued a $66.00 price objective on shares of Medivation in a research report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Medivation presently has an average rating of “Buy” and an average price target of $72.46.

The firm has a 50 day moving average of $63.13 and a 200-day moving average of $51.85. The stock’s market capitalization is $11.15 billion.

Medivation (NASDAQ:MDVN) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. The company had revenue of $206 million for the quarter, compared to the consensus estimate of $214.52 million. During the same quarter last year, the business posted $0.58 earnings per share. Medivation’s revenue was up 17.4% on a year-over-year basis. Equities analysts expect that Medivation Inc. will post $1.28 EPS for the current fiscal year.

In other news, SVP Andrew Kenneth William Powell sold 2,578 shares of Medivation stock in a transaction on Monday, June 6th. The stock was sold at an average price of $60.42, for a total transaction of $155,762.76. Following the sale, the senior vice president now directly owns 28,517 shares in the company, valued at approximately $1,722,997.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of large investors have recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management CO. LTD. raised its stake in shares of Medivation by 7.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. now owns 29,559 shares of the biopharmaceutical company’s stock valued at $1,429,000 after buying an additional 1,979 shares during the period. Bank of Montreal Can raised its stake in shares of Medivation by 8.0% in the fourth quarter. Bank of Montreal Can now owns 38,138 shares of the biopharmaceutical company’s stock valued at $1,844,000 after buying an additional 2,836 shares during the period. Advisors Asset Management Inc. raised its stake in shares of Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 3,688 shares during the period. Andra AP fonden raised its stake in shares of Medivation by 19.5% in the fourth quarter. Andra AP fonden now owns 30,600 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 5,000 shares during the period. Finally, I.G. Investment Management LTD. raised its stake in shares of Medivation by 10.2% in the fourth quarter. I.G. Investment Management LTD. now owns 56,420 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 5,200 shares during the period.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.